DXCM
Neutral signalScored 2026-10-21 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
DexCom, Inc.
- Nom
- DexCom, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $29.5B
- Employés
- 11,050
- PDG
- Jacob Steven Leach
- Site web
- https://www.dexcom.com
- Marché
- BBNXDRIOGCTKMMEDMMEDVPODD
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 54 524 titres (~4 531 522,41 $ US)
- Insiders
- SAYER KEVIN RHeller Bridgette P
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,293,261
Avg sell (VWAP, 90d window) $86.35 vs last close $78.57 (-9.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,147,945 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-20
- Liquidity
- Liquid $322,181,258/day · 20d vol
- Last synced
-
2026-10-26 21:10:24
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | Brown Michael Jon | Sell · S | 1,700 | $85.48 | $145,316 | Form 4 |
| 2026-09-28 | Stern Sadie | Sell · S · 10b5-1 | 2,565 | $86.15 | $220,975 | Form 4 |
| 2026-09-15 | Brown Michael Jon | Sell · S · 10b5-1 | 1,700 | $84.04 | $142,868 | Form 4 |
| 2026-09-10 | Sylvain Jereme M | Sell · S · 10b5-1 | 3,638 | $83.27 | $302,936 | Form 4 |
| 2026-08-27 | Stern Sadie | Sell · S · 10b5-1 | 2,565 | $88.37 | $226,669 | Form 4 |
| 2026-08-20 | SAYER KEVIN R | Sell · S · 10b5-1 | 97 | $91.41 | $8,867 | Form 4 |
| 2026-08-14 | Brown Michael Jon | Sell · S · 10b5-1 | 1,700 | $91.93 | $156,281 | Form 4 |
| 2026-08-12 | Heller Bridgette P | Sell · S · 10b5-1 | 1,012 | $88.29 | $89,349 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-04-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-22 | Michael T. McCaul | Purchase | $1,001 - $15,000 |
| 2025-06-16 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2025-06-02 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2025-05-15 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-05-08 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-04-08 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2025-04-08 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-04-07 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-03-13 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2025-02-25 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2024-12-31 | Kevin Hern | Sale (Full) | $50,001 - $100,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-12 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-21 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-28 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-07-19 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-06-17 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-02-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2021-07-01 | Kevin Hern | Purchase | $100,001 - $250,000 |
| 2021-06-03 | Thomas Suozzi | Sale (Full) | $15,001 - $50,000 |
| 2021-02-16 | Peter Meijer | Sale (Full) | $1,001 - $15,000 |
| 2020-12-24 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-12-22 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2020-10-02 | Susie Lee | Sale (Full) | $1,001 - $15,000 |
| 2020-09-16 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-08-13 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-05-11 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-01-10 | Thomas Suozzi | Purchase | $1,001 - $15,000 |
| 2020-01-09 | Thomas Suozzi | Purchase | $15,001 - $50,000 |
| 2019-07-16 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2019-06-20 | Brad Schneider | Sale (Full) | $100,001 - $250,000 |
| 2019-06-13 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2017-06-20 | Brad Schneider | Purchase | $100,001 - $250,000 |
| 2017-01-13 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-21 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
DXCM combines strong financial health (liquidity 80, fundamentals trend 85) with a meaningful clinical catalyst — the NEJM-published CONNECT Study validating G7 for Type 2 non-insulin users — that could structurally…
The first sentence of the analysis written for DXCM on 2026-10-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $254K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $254K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Congress Supports a bullish reading. 3 purchase disclosures year to date
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 1.88 · operating margin 20%
Suggested stop 68.46, nearest stored support minus 0.5 ATR(12.9% under the last close). Reward/risk to the next stored resistance is 0.03. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-20 DexCom''s G7 Shows Strong Results in Type 2 Diabetes CONNECT Study DXCM''s G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with Type 2 diabetes, supporting CGM adoption.
- 2026-10-20 DexCom (NASDAQ:DXCM) EVP Michael Jon Brown Sells 1,700 Shares of Company Stock DexCom, Inc. (NASDAQ: DXCM - Get Free Report) EVP Michael Brown sold 1,700 shares of the business''s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $85.48, for a total value of $145,316.00. Following the completion of the sale, the executive vice president directly owned 98,185 shares in
- 2026-10-17 DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence, especially for non-insulin Type 2 diabetes. The G7 15-Day sensor transition cut manufacturing costs, driving Q2 2026 gross margin up 400 bps to 64.1% and enabling 70% incremental operating margins. CONNECT study results published in NEJM reinforce DXCM''s clinical leadership, particularly among GLP-1 users, supporting expanded coverage and future growth.
- 2026-10-16 Glucose monitoring devices for type 2 diabetes benefit even those not on insulin Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of insulin dependence. We also report on a positive trial of a J&J pill in ulcerative colitis, and a discovery about ovaries after menopause.
- 2026-10-15 Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
- 2026-10-14 Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin. CONNECT participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%,.
- 2026-10-13 Here''s Why You Should Retain DexCom Stock in Your Portfolio for Now DexCom''s strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.
- 2026-10-08 96,427 Shares of DexCom, Inc. $DXCM Bought by HWG Holdings LP HWG Holdings LP acquired a new stake in shares of DexCom, Inc. (NASDAQ: DXCM) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 96,427 shares of the medical device company''s stock, valued at approximately $8,321,000. DexCom makes up approximately 1.9% of HWG
- 2026-10-06 Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading [url="]DEXCOM[/url], INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of [url="]Dexcom U[/url], the
- 2026-10-06 Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company''s one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.Now in its fifth year, this marks the program''s largest and most expansive roster to date, featuring 27 college athletes, 12 new and 15 returning, across 13 sports. The expansion is backed by new research showing that programs l.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 60.1% | 60.5% | 63.2% | 64.7% | 68.6% | |
| Ebit Margin | 23.7% | 18.1% | 20.2% | 14.1% | 11.3% | |
| Ebitda Margin | 29.1% | 23.4% | 25.3% | 19.4% | 15.4% | |
| Operating Profit Margin | 19.6% | 14.9% | 16.5% | 13.4% | 10.9% | |
| Pretax Profit Margin | 23.3% | 17.6% | 19.6% | 13.4% | 10.5% | |
| Continuous Operations Profit Margin | 17.9% | 14.3% | 14.9% | 11.7% | 8.9% | |
| Net Profit Margin | 17.9% | 14.3% | 14.9% | 11.7% | 8.9% | |
| Bottom Line Profit Margin | 18.2% | 14.6% | 15.3% | 12.1% | 9.3% | |
| Current Ratio | 1.883 | 1.467 | 2.844 | 1.995 | 5.112 | |
| Quick Ratio | 1.589 | 1.282 | 2.485 | 1.828 | 4.616 | |
| Solvency Ratio | 0.303 | 0.181 | 0.173 | 0.152 | 0.110 | |
| Cash Ratio | 0.428 | 0.207 | 0.364 | 0.349 | 1.460 | |
| Price To Earnings Ratio | 31.014 | 53.267 | 86.174 | 128.682 | 239.714 | |
| Price To Earnings Growth Ratio | 0.666 | 38.352 | 1.354 | 2.252 | -4.187 | |
| Forward Price To Earnings Growth Ratio | 0.666 | 38.352 | 1.354 | 2.252 | -4.187 | |
| Price To Earnings Diluted Ratio | 31.756 | 54.768 | 95.454 | 141.550 | 263.216 | |
| Price To Earnings Diluted Growth Ratio | 0.673 | 5.933 | 1.527 | 2.489 | -4.398 | |
| Price To Book Ratio | 9.431 | 14.966 | 23.155 | 20.685 | 25.433 | |
| Price To Sales Ratio | 5.555 | 7.803 | 13.223 | 15.154 | 21.212 | |
| Price To Free Cash Flow Ratio | 24.042 | 49.893 | 93.571 | 144.718 | 974.436 | |
| Price To Operating Cash Flow Ratio | 17.976 | 31.802 | 63.993 | 65.864 | 117.373 | |
| Debt To Assets Ratio | 0.219 | 0.399 | 0.414 | 0.398 | 0.437 | |
| Debt To Equity Ratio | 0.506 | 1.231 | 1.254 | 1.006 | 1.057 | |
| Debt To Capital Ratio | 0.336 | 0.552 | 0.556 | 0.502 | 0.514 | |
| Long Term Debt To Capital Ratio | 0.311 | 0.370 | 0.541 | 0.360 | 0.493 | |
| Financial Leverage Ratio | 2.309 | 3.084 | 3.028 | 2.529 | 2.416 | |
| Working Capital Turnover Ratio | 2.860 | 1.903 | 1.542 | 1.214 | 0.848 | |
| Operating Cash Flow Ratio | 0.672 | 0.337 | 0.481 | 0.364 | 0.614 | |
| Operating Cash Flow Sales Ratio | 0.309 | 0.245 | 0.207 | 0.230 | 0.181 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.748 | 0.637 | 0.684 | 0.455 | 0.120 | |
| Debt Service Coverage Ratio | 60.459 | 0.664 | 36.837 | 0.652 | 17.963 | |
| Interest Coverage Ratio | 49.825 | 31.579 | 29.443 | 21.032 | 14.138 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.822 | 0.000 | 0.867 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 1.037 | 0.382 | 0.289 | 0.312 | 0.205 | |
| Capital Expenditure Coverage Ratio | 3.963 | 2.758 | 3.164 | 1.835 | 1.137 | |
| Dividend Paid And Capex Coverage Ratio | 3.963 | 2.758 | 3.164 | 1.835 | 1.137 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 19.411 | 35.370 | 54.463 | 80.662 | 140.473 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 60.1% | ▼-0.4% | ▼-3.3% |
| Ebit Margin | 23.7% | ▲5.7% | ▲6.3% |
| Ebitda Margin | 29.1% | ▲5.7% | ▲6.6% |
| Operating Profit Margin | 19.6% | ▲4.7% | ▲4.5% |
| Pretax Profit Margin | 23.4% | ▲5.8% | ▲6.5% |
| Continuous Operations Profit Margin | 17.9% | ▲3.6% | ▲4.4% |
| Net Profit Margin | 17.9% | ▲3.6% | ▲4.4% |
| Bottom Line Profit Margin | 18.2% | ▲3.6% | ▲4.3% |
| Current Ratio | 1.883 | ▲0.415 | ▼-0.777 |
| Quick Ratio | 1.589 | ▲0.307 | ▼-0.771 |
| Solvency Ratio | 0.303 | ▲0.122 | ▲0.119 |
| Cash Ratio | 0.428 | ▲0.222 | ▼-0.133 |
| Price To Earnings Ratio | 31.014 | ▼-22.253 | ▼-76.756 |
| Price To Earnings Growth Ratio | 0.666 | ▼-37.686 | ▼-7.022 |
| Forward Price To Earnings Growth Ratio | 0.666 | ▼-37.686 | ▼-7.022 |
| Price To Earnings Diluted Ratio | 31.756 | ▼-23.012 | ▼-85.593 |
| Price To Earnings Diluted Growth Ratio | 0.673 | ▼-5.260 | ▼-0.572 |
| Price To Book Ratio | 9.431 | ▼-5.535 | ▼-9.303 |
| Price To Sales Ratio | 5.555 | ▼-2.248 | ▼-7.034 |
| Price To Free Cash Flow Ratio | 24.042 | ▼-25.852 | ▼-233.290 |
| Price To Operating Cash Flow Ratio | 17.976 | ▼-13.826 | ▼-41.426 |
| Debt To Assets Ratio | 0.219 | ▼-0.180 | ▼-0.154 |
| Debt To Equity Ratio | 0.506 | ▼-0.725 | ▼-0.505 |
| Debt To Capital Ratio | 0.336 | ▼-0.216 | ▼-0.156 |
| Long Term Debt To Capital Ratio | 0.311 | ▼-0.059 | ▼-0.104 |
| Financial Leverage Ratio | 2.309 | ▼-0.775 | ▼-0.364 |
| Working Capital Turnover Ratio | 2.860 | ▲0.957 | ▲1.187 |
| Operating Cash Flow Ratio | 0.672 | ▲0.335 | ▲0.179 |
| Operating Cash Flow Sales Ratio | 0.309 | ▲0.064 | ▲0.075 |
| Free Cash Flow Operating Cash Flow Ratio | 0.748 | ▲0.110 | ▲0.219 |
| Debt Service Coverage Ratio | 60.459 | ▲59.795 | ▲37.144 |
| Interest Coverage Ratio | 49.825 | ▲18.246 | ▲20.622 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-0.822 | ▼-0.338 |
| Operating Cash Flow Coverage Ratio | 1.037 | ▲0.654 | ▲0.592 |
| Capital Expenditure Coverage Ratio | 3.963 | ▲1.206 | ▲1.392 |
| Dividend Paid And Capex Coverage Ratio | 3.963 | ▲1.206 | ▲1.392 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 19.411 | ▼-15.959 | ▼-46.665 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $25.90B | $31.47B | $47.90B | $44.10B | $51.94B | |
| Enterprise value | $26.37B | $33.45B | $49.93B | $45.60B | $53.04B | |
| EV / Sales | 5.66x | 8.29x | 13.78x | 15.67x | 21.66x | |
| EV / Op. cash flow | 18.30x | 33.80x | 66.70x | 68.11x | 119.87x | |
| EV / Free cash flow | 24.48x | 53.03x | 97.53x | 149.65x | 995.17x | |
| EV / EBITDA | 19.41x | 35.37x | 54.46x | 80.66x | 140.47x | |
| Net debt / EBITDA | 0.35x | 2.10x | 2.21x | 2.66x | 2.93x | |
| Current ratio | 1.88x | 1.47x | 2.84x | 2.00x | 5.11x | |
| Income quality | 1.72x | 1.72x | 1.38x | 1.96x | 2.86x | |
| Graham number | $18 | $13 | $13 | $10 | $8 | |
| Graham net-net | -$1 | -$2 | -$1 | -$0 | $1 | |
| Tax burden | 76.8% | 81.3% | 76.2% | 87.3% | 84.5% | |
| Interest burden | 98.3% | 97.4% | 97.2% | 95.5% | 93.2% | |
| Working capital | $1.89B | $1.37B | $2.87B | $1.83B | $2.96B | |
| Invested capital | $3.62B | $2.90B | $4.21B | $3.16B | $3.91B | |
| Return on assets | 13.2% | 8.9% | 8.6% | 6.3% | 4.4% | |
| Operating ROA | 14.2% | 9.4% | 10.3% | 7.6% | 5.8% | |
| Return on tangible assets | 13.4% | 9.1% | 8.9% | 6.6% | 4.4% | |
| Return on equity | 30.5% | 27.4% | 26.2% | 16.0% | 10.6% | |
| Return on invested capital | 16.6% | 10.2% | 9.6% | 7.9% | 5.3% | |
| Return on capital employed | 21.7% | 16.9% | 12.7% | 11.0% | 6.3% | |
| Earnings yield | 3.2% | 1.8% | 1.1% | 0.8% | 0.4% | |
| Free cash flow yield | 4.2% | 2.0% | 1.1% | 0.7% | 0.1% | |
| Capex / Op. cash flow | 25.2% | 36.3% | 31.6% | 54.5% | 88.0% | |
| Capex / Depreciation | 144.4% | 164.8% | 127.2% | 234.0% | 381.6% | |
| Capex / Sales | 7.8% | 8.9% | 6.5% | 12.5% | 15.9% | |
| SG&A / Sales | 27.7% | 31.9% | 32.7% | 34.6% | 33.1% | |
| R&D / Sales | 12.9% | 13.7% | 14.0% | 16.6% | 24.7% | |
| Stock comp / Sales | 3.4% | 4.2% | 4.2% | 4.3% | 4.6% | |
| Intangibles / Total assets | 1.5% | 1.9% | 2.5% | 3.7% | 1.2% | |
| Days sales outstanding | 101d | 94d | 100d | 94d | 77d | |
| Days payables outstanding | 68d | 79d | 76d | 85d | 90d | |
| Operating cycle | 224d | 218d | 253d | 203d | 247d | |
| Cash conversion cycle | 157d | 139d | 177d | 119d | 157d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years